Preliminary evaluation of safety of conditionally replication adenovirus M4

  • Caihong Chen (陈彩虹)
  • Haiyan Fang (方海燕)
  • Yumei Rao (饶玉梅)
  • Peng Wu (吴 鹏)
  • Yang He (何 杨)
  • Ding Ma (马 丁)
  • Qinglei Gao (高庆蕾)
Article
  • 47 Downloads

Summary

Conditionally replication adenovirus M4, which was constructed in our lab, was proved to have good clinical application prospect for its good anti-tumor and anti-metastasis effect. However, clinically applying M4 faces many problems. One of the most important is the safety of M4. In this study, we investigated the safety of M4 by comparing with Adv-TK, which was proved to be safe in I–III phase clinical trials. M4 and Adv-TK were injected into mice via the tail vein separately, and the mice were sacrificed at the indicated time. Blood was collected for biochemical tests, the liver was harvested for hematoxylin and eosin (H&E) staining and viral quantification, and splenic lymphocytes were separated for adenovirus specific cellular immune response. Our results showed that M4 had no obvious effect on mouse general symptoms. A transient reversible infiltration of inflammatory cells in collect abbacy was only observed in M4 group, and a transient slight increase in Cr level was detected both after M4 and Adv-TK injection. The adenovirus specific cellular immune response induced by M4 was similar to that by Adv-TK, and the distribution and metabolism of M4 in the mouse liver were also similar to those of Adv-TK. It was concluded that conditionally replication adenovirus M4 had the same safety as Adv-TK. The study provides safety basis for the coming clinical trials of M4.

Key words

conditionally replication adenovirus M4 safety blood biochemistry distribution 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther, 2004,15(11):1034–1044PubMedCrossRefGoogle Scholar
  2. 2.
    Emunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res, 2000,60(22):6359–6366Google Scholar
  3. 3.
    DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res, 2001,61(20):7464–7472PubMedGoogle Scholar
  4. 4.
    Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double- suicide gene therapy in combination with conventional- dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res, 2003,63(21):7497–7506PubMedGoogle Scholar
  5. 5.
    Page JG, Tian B, Schweikart K, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol, 2007,196(4):389 e1–9; discussion 389 e9–10PubMedCrossRefGoogle Scholar
  6. 6.
    Han Z, Hong Z, Chen C, et al. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis, 2009,30(12):2014–2022PubMedCrossRefGoogle Scholar
  7. 7.
    Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007,13(19):5847–5854PubMedCrossRefGoogle Scholar
  8. 8.
    Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines, 2009,8(6):761–77PubMedCrossRefGoogle Scholar
  9. 9.
    Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther, 2002,4(5):423–434PubMedGoogle Scholar
  10. 10.
    Varnavski AN, Calcedo R, Bove M, et al. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and preimmunized mice. Gene Ther, 2005,12(5):427–436PubMedCrossRefGoogle Scholar
  11. 11.
    Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res, 2003,9(2):693–702PubMedGoogle Scholar
  12. 12.
    Lu W, Zheng S, Li XF, et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol, 2004,10(24): 3634–3638PubMedGoogle Scholar
  13. 13.
    Su C, Cao H, Tan S, et al. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci, 2008,106(1):242–250PubMedCrossRefGoogle Scholar
  14. 14.
    Page C, Huang M, Jin X, et al. Elevated phosphorylation of AKT and STAT3 in prostate, breast, and cervical cancer cells. Int J Oncol, 2000,17(1):23–28PubMedGoogle Scholar
  15. 15.
    Mora LB, Buettner R, Seigne J, et al. Constitutive activation of STAT3 in human prostate tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res, 2002, 62(22):6659–6666PubMedGoogle Scholar
  16. 16.
    Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol, 2005,58(8):833–838PubMedCrossRefGoogle Scholar
  17. 17.
    Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006,107(11):2730–2740PubMedCrossRefGoogle Scholar
  18. 18.
    Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets, 2004,8(5):409–422PubMedCrossRefGoogle Scholar
  19. 19.
    Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 2000,19(56): 6613–6626PubMedCrossRefGoogle Scholar
  20. 20.
    Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer, 2004,4(2):97–105PubMedCrossRefGoogle Scholar
  21. 21.
    Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res, 2008,18(2):254–267PubMedCrossRefGoogle Scholar
  22. 22.
    Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010,115(6): 1131–1136PubMedCrossRefGoogle Scholar
  23. 23.
    Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med, 2010,363(12):1117–1127PubMedCrossRefGoogle Scholar
  24. 24.
    Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem, 2009,108(4):778–790PubMedCrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Caihong Chen (陈彩虹)
    • 1
    • 2
  • Haiyan Fang (方海燕)
    • 1
  • Yumei Rao (饶玉梅)
    • 1
    • 3
  • Peng Wu (吴 鹏)
    • 1
  • Yang He (何 杨)
    • 1
  • Ding Ma (马 丁)
    • 1
  • Qinglei Gao (高庆蕾)
    • 1
  1. 1.Cancer Biology Research Center, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Center of Reproductive Medicinethe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  3. 3.Department of Obstetrics and Gynecologythe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations